Ardena is pleased to announce that a Commercial Agency Agreement for Taiwan (ROC) has been signed with the company Medi-Point North Healthcare Co., Ltd.
Medi-Point North Healthcare is covering all key stages from drug discovery over regulatory approval to commercialization and is well up to date with Taiwan FDA latest regulations and guidelines.
The company will develop the market in Taiwan (ROC) for the entire Ardena services platform.
The Taiwanese Stock Exchange list includes around 125 public biotech companies.
The biotech market represents an important business opportunity for Ardena in addition to the 220 privately owned Taiwanese pharmaceutical companies.
The commercial agency shall commence on December 01st, 2020.
more recommended stories
Autoimmune Disorders: ADA2 as a Therapeutic TargetAdenosine deaminase 2 (ADA2) has emerged.
Kaempferol: A Breakthrough in Allergy ManagementKaempferol, a dietary flavonoid found in.
Early Milk Cereal Drinks May Spur Infant Weight GainNew research published in Acta Paediatrica.
TaVNS: A Breakthrough for Chronic Insomnia TreatmentA recent study conducted by the.
First-of-Its-Kind Gene-Edited Pig Kidney: Towana’s New LifeSurgeons at NYU Langone Health have.
Just-in-Time Training Improves Success & Patient SafetyA study published in The BMJ.
ChatGPT Excels in Medical Summaries, Lacks Field-Specific RelevanceIn a recent study published in.
Study finds automated decision minimizes high-risk medicine combinations in ICU patientsA multicenter study coordinated by Amsterdam.
Study Discovers Connection Between Omicron Infection and Brain Structure Changes in MenA recent study in the JAMA.
Advancing COPD Prognosis: Deep Learning ModelsResearchers conducted a meta-analysis in a.
Leave a Comment